Tradestie Institutional Equity Comparison Engine
NGNE vs CGEN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CGEN Overall Edge
CGEN Captures Institutional Edge (3โ1 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Compugen Ltd (CGEN) driven by superior Valuation, Growth & Margin, Momentum & Technical while NGNE counters with relative strength in Options & Structure. Fundamentally, NGNE trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CGEN at 12.4x Forward P/E and 41.3% operating margin (+102.1% YoY). In options structure, NGNE sits in BREAKDOWN (14th %ile IV; Dealer Gamma Walls on Pro) against CGEN sits in BREAKDOWN (57th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CGEN
NGNE N/M vs CGEN 12.4x Fwd P/E
Growth & Margin Winner
CGEN
Op Margin 0.0% vs 41.3% ยท YoY +0.0% vs +102.1%
Momentum & Technical Winner
CGEN
1Y +1.4% vs +23.2% ยท 52W Pos 26% vs 33%
Options & Structure Winner
NGNE
BREAKDOWN (14th %ile IV) vs BREAKDOWN (57th %ile IV)
NGNE
NASDAQ
Neurogene, Inc. Common Stock
Pharmaceutical Preparations
$23.10
-0.86% 1D
Market Cap
$482.3M
1M Return
-4.43%
1Y Return
+1.45%
Forward P/E
N/M
Unified AI Score
44.2 / 100
HOLD
Tech 28.0
Fund 49.0
Flow 70.0
Mom 60.0
CGEN
NASDAQ
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap
$193.2M
1M Return
+2.54%
1Y Return
+23.17%
Forward P/E
12.4x
Unified AI Score
49.8 / 100
HOLD
Tech 53.0
Fund 52.0
Flow 55.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
NGNE +1.45%
CGEN +23.17%
Spread: +21.72 pp (CGEN Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NGNE Revenue | CGEN Revenue | NGNE Op. Margin | CGEN Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2016 | N/A | $0M | N/A | -4576.3% | CGEN |
| FY2018 | $30M | $20M | -130.5% | -130.5% | Tie |
| FY2020 | N/A | $0M | N/A | -1574.8% | CGEN |
| FY2021 | N/A | $10M | N/A | -584.6% | CGEN |
| FY2022 | N/A | $10M | N/A | -471.7% | CGEN |
| FY2023 | N/A | $30M | N/A | -38.8% | CGEN |
| FY2024 | $0M | $30M | -8930.3% | -53.4% | CGEN |
| FY2025 | N/A | $70M | N/A | 43.1% | CGEN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NGNE | CGEN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $482.3M | $193.2M | Larger Scale | NGNE |
| Trailing P/E Ratio Valuation | N/M | 5.2x | Lower Multiple | CGEN |
| Forward P/E Ratio Valuation | N/M | 12.4x | Lower Multiple | CGEN |
| Revenue Growth (YoY) Growth | +0.0% | +102.1% | Higher Growth | CGEN |
| Operating Margin (TTM) Profitability | 0.0% | 41.3% | Higher Margin | CGEN |
| Net Profit Margin Profitability | 0.0% | 47.9% | Higher Margin | CGEN |
| Return on Equity (ROE) Capital Efficiency | -38.4% | 57.2% | Higher ROE | CGEN |
| 52-Week Range Position Momentum | 26% ($16โ$44) | 33% ($1โ$3) | Stronger Trend | CGEN |
| Beta / 30D Volatility Risk Regime | 1.54ฮฒ ยท 87% Vol | 1.44ฮฒ ยท 62% Vol | Lower Realized Risk | CGEN |
| Unified Institutional Score Composite Signal | 44.2 / 100 (HOLD) | 49.8 / 100 (HOLD) | Higher Composite | CGEN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full NGNE vs CGEN Buy Guide
NGNE
BREAKDOWN
92d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
14th %ile
IV Regime
Compressed (<25th %ile)
CGEN
BREAKDOWN
143d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
57th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither NGNE nor CGEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.